Boris Gorovits

Company: Sana Biotechnology

Job title: Vice President - Preclinical Translational & Bioanalytical

Seminars:

Detecting Pre-Existing Antibodies to AAV Gene Therapies 11:00 am

One of the inherent challenges to effective AAV gene therapy treatment is the prior exposure and neutralizing antibody (NAb) generation in a large number of target populations. The methods used for testing for seropositivity prior to transfer remains a hotly-debated topic, with no universal test or titer currently deployed as an industry standard for detecting…Read more

day: Pre-Conference Day